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Simvastatin Improves Disturbed Endothelial
Barrier Function
Geerten P. van Nieuw Amerongen, PhD; Mario A. Vermeer, BSc; Pascale Nègre-Aminou, PhD;
Jan Lankelma, PhD; Jef J. Emeis, PhD; Victor W.M. van Hinsbergh, PhD
Background—Recent clinical trials have established that inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme
A reductase (statins) reduce the risk of acute coronary events. These effects of statins cannot be fully explained by their
lipid-lowering potential. Improved endothelial function may contribute to the positive effects of statin treatment.
Methods and Results—In the present study, we report that simvastatin reduces endothelial barrier dysfunction, which is
associated with the development of atherosclerosis. Treatment of human umbilical vein endothelial cells for 24 hours
with 5 mmol/L simvastatin reduced the thrombin-induced endothelial barrier dysfunction in vitro by 5563%, as assessed
by the passage of peroxidase through human umbilical vein endothelial cell monolayers. Similar effects were found on
the thrombin-induced passage of 125I-LDL through human aortic endothelial cell monolayers. This reduction in barrier
dysfunction by simvastatin was both dose and time dependent and was accompanied by a reduction in the
thrombin-induced formation of stress fibers and focal adhesions and membrane association of RhoA. Simvastatin
treatment had no effect on intracellular cAMP levels. In Watanabe heritable hyperlipidemic rabbits, treatment for 1
month with 15 mg/kg simvastatin reduced vascular leakage in both the thoracic and abdominal part of the aorta, as
evidenced by the Evans blue dye exclusion test. The decreased permeability was not accompanied by a reduction of oil
red O–stainable atherosclerotic lesions.
Conclusions—These data show that simvastatin, in a relatively high concentration, improves disturbed endothelial barrier
function both in vitro and in vivo. The data also support the beneficial effects of simvastatin in acute coronary events
by mechanisms other than its lipid-lowering effect. (Circulation. 2000;102:2803-2809.)
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Recent clinical trials have shown that statins, inhibitors of3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase, the rate-limiting enzyme of cholesterol synthesis in
the liver, are effective in the prevention of acute coronary
events. Further analysis of these studies suggests that the
benefits of statin therapy cannot be fully explained on the
basis of reductions in plasma cholesterol levels.1,2 Recent
studies have demonstrated that treatment of hypercholester-
olemic patients with statins improves endothelial function
and vasomotion.3,4 These effects of statins on endothelial
function can be fast in onset, inasmuch as an improvement of
endothelial function was reported within 1 month of simva-
statin therapy in patients with moderate serum cholesterol.5
Experimental atherosclerosis in hypercholesterolemia
models is associated with changes in endothelial integrity
(see review6). Additionally, during the development of ath-
erosclerosis, the permeability of the vessel wall for LDL
increases (see review7). Because gross endothelial loss prob-
ably only occurs very late in the development of atheroscle-
rosis, dysfunction of the intact endothelial layer provides a
more likely explanation for the increase in permeability.
The endothelial actin cytoskeleton is important in main-
taining the structural integrity of the endothelium.8 The
junction-associated actin filament system forms a dense
peripheral band of F-actin and is the most prominent assem-
bly in the majority of endothelial cells.8 Activation of the
endothelium by inflammatory mediators results in a contrac-
tion process at the margins of the cell. Small gaps between
neighboring cells are formed, increasing the permeability of
the endothelium. In vitro, these changes in permeability are
accompanied by the formation of long F-actin filaments or
stress fibers.9 In vivo, endothelial stress fibers are found in
areas of altered flow. The function of these stress fibers is not
precisely known at the moment, but they could have contrac-
tile properties.10
In the present study, we investigated whether simvastatin
could improve disturbed endothelial barrier function, in both
in vitro and in vivo models of endothelial perturbation.
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Methods
Materials
Tissue culture plastics and Transwells (diameter 0.65 cm, pore size
3 mm) were obtained from Corning Costar; cell culture reagents were
as described previously.9 Bovine thrombin was from Leo Pharma-
ceutical Products. Horseradish peroxidase (HRP), Evans blue, oil red
O, and anti-vinculin immunoglobulin were obtained from Sigma
Chemical Co. Rhodamine-phalloidin was from Molecular Probes.
Rabbit anti-mouse IgG-FITC was from Dakopatts. Simvastatin-
lactone used in the in vitro studies was from Merck, Sharp & Dohme,
and simvastatin-lactone used in the in vivo studies was from Sankyo.
125I was purchased from Amersham. Pyrogen-free human serum
albumin (HSA) was from the Central Laboratory of the Blood
Transfusion Service, Amsterdam, the Netherlands.
Cell Culture and Evaluation of Barrier Function
In Vitro
Human endothelial cells were isolated and cultured as described
previously.11 Cells were seeded at high density and grown on
fibronectin-coated polycarbonate filters of the Transwell system for
4 to 6 days until highly confluent monolayers were obtained.9,12
Culture medium was renewed every other day (medium 199, 10%
human serum, 10% newborn calf serum, 150 mg/mL crude endothe-
lial cell growth factor, 5 U/mL heparin, 100 IU/mL penicillin, and
100 mg/mL streptomycin). Subsequently, cells were treated with
simvastatin (0.1 to 5.0 mmol/L) for the indicated time points (usually
24 hours) in culture medium. After treatment with simvastatin, cells
were washed with medium 199/1% HSA to remove serum, incubated
for 1 hour in medium 199/1% HSA, and subsequently stimulated
with thrombin. Barrier function was evaluated by the transfer of HRP
or 125I-LDL across human umbilical vein endothelial cell (HUVEC,
after 1 passage) or human aortic endothelial cell (EC, after 4
passages) monolayers. In short, HRP or 125I-LDL was added to the
upper compartment of the Transwells, samples were taken from the
lower compartment at various time intervals, and the volume was
adjusted by medium 199/1% HSA. HRP concentration was deter-
mined spectrophotometrically in each sample with peroxide and
tetramethyl benzidine.125I-LDL concentration was determined in a
g-counter after trichloroacetic acid precipitation to correct for
degradation of the LDL particle.
Preparation and Iodination of LDLs
LDL was isolated from fresh serum prepared from the blood of
healthy volunteers by gradient ultracentrifugation13 and labeled with
125I as previously described.12
Extraction and Assay of Intracellular
cAMP Levels
Intracellular cAMP levels were determined by radioimmunoassay
from Amersham as described previously.9,11
Immunocytochemistry
The presence of vinculin and F-actin was visualized by indirect
immunofluorescence with mouse anti-vinculin antibody and by
direct staining with rhodamine-phalloidin with use of a confocal
laser scan microscope (type TCS 4D, Leica Heidelberg). Overlaying
of pictures was accomplished with Photo-Paint software (version
6.00, 1995, Corel Co).
Detection of Cytosolic and
Membrane-Bound RhoA
Confluent endothelial monolayers were preincubated for 24 hours
with 5 mmol/L simvastatin in normal culture medium. One hour
before lysis, the cell culture medium was replaced by medium
199/1% HSA. After they were washed with PBS, the cells were lysed
in 300 mL/10 cm2 ice-cold hypotonic lysis buffer (5 mmol/L
Tris-HCl, pH 7.0, 5 mmol/L NaCl, 1 mmol/L CaCl2, 2 mmol/L
EGTA, 1 mmol/L MgCl2, 2 mmol/L dithiothreitol, and freshly added
protease inhibitors [Complete, Boehringer]) and incubated for 30
minutes on ice. Cells were scraped and sucked 5 times through a
25-gauge needle. Membrane and cytosolic fractions were separated
by centrifugation at 100 000g for 1 hour. The pellet was dissolved in
an equal volume of lysis buffer11% Triton X-100. Proteins were
separated on SDS-PAGE and transferred to polyvinylidine difluo-
ride, and immunoblotting was performed with the use of an antibody
to RhoA (Santa Cruz Biotechnology Inc). Immunodetection was
accomplished with the use of a goat anti-rabbit secondary antibody
and an enhanced chemoluminescence kit (ECL kit, Amersham
Corp).
Animals
Sixteen-month-old Watanabe heritable hyperlipidemic rabbits were
obtained from the Oriental Yeast Co, Tokyo, Japan. They were
housed individually and fed standard rabbit chow ad libitum, with
water supplied ad libitum. For 4 weeks before euthanasia, the
animals received simvastatin-lactone (15.0 mg/kg body wt) daily, in
addition to the standard rabbit chow.
Cholesterol Measurement
Total serum cholesterol was determined by using a commercially
available enzymatic kit (Roche Diagnostics).
Evaluation of Vascular Leakage and
Atherosclerosis
Animals were sedated with Hypnorm (0.4 mL/kg IM; Janssen
Pharmaceutical), mildly anticoagulated with heparin (500 U/rabbit
IV), and euthanized with pentobarbital sodium (2.5 mL/kg IV).
Aortas were rapidly removed and cleaned from the adjacent tissue.
They were perfused with medium 199 buffered with Hanks’ salts,
100 IU/mL penicillin, 100 mg/mL streptomycin, and 1% HSA to
remove blood cells; subsequently, with Evans blue in medium 199
(0.3% [wt/vol]) for 5 minutes; and finally, with medium 199 to
remove unbound Evans blue. They were then fixed with 3.7%
buffered formaldehyde. Aortas were opened longitudinally and
photographed en face with use of a digital Nikon Coolpix 900
camera. Evans blue staining was quantified 4-fold with Tina image
analysis software (Raytest), and optical density was expressed in
arbitrary units per square millimeter.
Subsequently, the extent of atherosclerosis was assessed by
staining the Evans blue–treated aortic segments with oil red O and
evaluated.
Statistical Analysis
Data are reported as mean6SEM. Comparisons between .2 groups
were made by 1-way ANOVA, followed by a Bonferroni-adjusted x2
test. Comparisons of time curves of 2 groups were made by
repeated-measures MANOVA, and individual group comparisons
were performed by a Student t test for post hoc comparisons of the
means. Differences were considered significant at the P,0.05 level.
Results
Effects of Simvastatin on In Vitro Endothelial
Barrier Function
Confluent HUVEC and human aortic EC monolayers were
incubated for 24 hours in medium 199 containing 5 mmol/L
simvastatin in the presence of serum to evaluate the effect on
cell morphology (Figure 1). Simvastatin-treated ECs re-
mained tightly confluent, but cells were slightly elongated
(which was most easily visible in aortic monolayers) with a
condensed cytoplasm around the nucleus.
To test whether simvastatin influences endothelial barrier
function, HUVECs were grown to confluence on porous
filters, and the passage of a marker protein (HRP, 42 to 44
kDa) was measured. Pretreatment with 5 mmol/L simvastatin
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for 24 hours slightly increased HRP passage. However, the
thrombin-induced HRP passage was significantly decreased
(Figure 2A). This simvastatin pretreatment inhibited
thrombin-induced HRP passage by 5563% during a 1-hour
incubation period (mean6SEM, 5 different cultures in trip-
licate). The reduction was concentration dependent (Figure
2B) and was maximal at 5 mmol/L simvastatin. Higher
concentrations were not used because they affected basal EC
barrier function. Lower concentrations of simvastatin re-
quired longer incubation periods. Preincubation with 0.5
mmol/L simvastatin for 96 hours reduced the thrombin-
enhanced HRP passage by 3565% (mean6SEM; 6 filter
cultures of 2 different donors, Figure 2C). Coincubation with
mevalonate fully abolished the effect of simvastatin on cell
morphology (not shown) and thrombin-induced HRP passage
(Figure 2B), indicating that simvastatin reduced the
thrombin-induced HRP passage by inhibition of HMG-CoA
reductase. Simvastatin inhibited the thrombin-induced HRP
passage in a time-dependent manner (Figure 2D). This
inhibition was maximal after 8 hours of simvastatin pretreat-
ment and continued for at least 24 hours. Because atheroscle-
rosis is associated with an enhanced passage of LDL across
the aortic endothelium and an increase in the accumulation of
LDL in the aortic wall,7 we preincubated human aortic EC
monolayers with simvastatin and measured its effect on
(thrombin-induced) 125I-LDL passage. Simvastatin slightly
increased basal aortic endothelial permeability but attenuated
thrombin-enhanced LDL passage and was maximally effec-
tive at 2 mmol/L (Figure 2E).
Effect of Simvastatin on Permeability Does Not
Involve cAMP or Endothelial NO Synthase
Elevation of intracellular cAMP levels is known to improve
endothelial barrier function.14 When HUVECs were preincu-
bated with 5 mmol/L simvastatin for 24 hours, cAMP con-
centrations remained unaltered both under basal conditions
(2.660.2 and 1.960.4 pmol per 3.53105 cells in control and
simvastatin-pretreated cells, respectively) and after a
2-minute stimulation of the cells with 1 U/mL thrombin
(2.560.8 and 2.160.4 pmol per 3.53105 cells, respectively)
or after a 30-minute stimulation (2.660.1 and 2.160.2 pmol
per 3.53105 cells, respectively) (3 experiments). As a posi-
tive control, cells were pretreated for 15 minutes with 10
mmol/L forskolin, which raised intracellular cAMP concen-
Figure 1. Effect of simvastatin on morphology of HUVECs of
passage number 1 (A and B) and human aortic ECs of passage
number 4 (C and D). Phase-contrast micrographs of control
cells (A and C) and of cells preincubated for 24 hours with 5
mmol/L simvastatin (B and D).
Figure 2. Effect of simvastatin (Simva) on
human endothelial barrier function. A,
HUVEC monolayers were preincubated
for 24 hours with 5 mmol/L Simva (, )
or without Simva (E, F). HRP passage
was measured under basal conditions (E,
) and after exposure to 1 U/mL throm-
bin (F, ) as described in Methods. Val-
ues are mean6SEM of 2 different cul-
tures in triplicate. Interaction between
time and Simva treatment was significant
(P50.000) for thrombin-stimulated cells.
*P,0.05 for Simva-pretreated vs nonpre-
treated cells that were stimulated with
thrombin. B, HUVEC monolayers were
pretreated for 24 hours with various con-
centrations of Simva (0.1, 0.5, 1.0, 2.5, or
5.0 mmol/L) in presence or absence of
100 mmol/L mevalonic acid (1Meva).
HRP passage was measured 1 hour after
exposure to 1 U/mL thrombin. Values are
mean6SEM of 2 different cultures in trip-
licate. There was a significant difference
between HRP passage of various
thrombin-stimulated groups (P50.000). C,
Prolonged preincubation (96 hours) with 0.5 mmol/L Simva enhances effect of Simva on thrombin-induced HRP passage through
HUVEC monolayers. HRP passage was measured 1 hour after exposure to 1 U/mL thrombin (hatched bars) or without stimulation (stip-
pled bars). Values are mean6SEM of 6 filter cultures of 2 donors. D, HUVEC monolayers were pretreated for indicated time periods
with 5 mmol/L Simva, and HRP passage was subsequently measured under basal conditions (stippled bars) or 1 hour after stimulation
with 1 U/mL thrombin (hatched bars). Values are mean6SD of 1 representative experiment of 3 experiments. E, Human aortic endothe-
lial monolayers were pretreated for 24 hours with 2 mmol/L Simva. 125I-LDL passage was measured 1 hour after exposure to 1 U/mL
thrombin (hatched bars) or sham treatment (stippled bars). Values are mean6SEM of 3 independent experiments in triplicate. *P,0.05
Simva-pretreated cells vs nonpretreated cells (B, C, and E).
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tration to 9.060.4 pmol per 3.53105 cells. This excludes
elevation of cAMP as the mechanism of action.
Statins can increase the cellular amount of endothelial NO
synthase (eNOS).15,16 NO counteracts the thrombin-induced
permeability in our model.17 Although prolonged incubation
(.24 hours) of HUVECs and aortic ECs with simvastatin
indeed increased the level of eNOS protein, simvastatin had
no effect on eNOS protein expression within the 24-hour
incubation period in our experimental conditions (Western
blotting, data not shown).
Effect of Simvastatin on Localization of
Vinculin and F-Actin of Basal and Thrombin-
Stimulated Monolayers
The actin cytoskeleton of ECs is important in maintaining the
structural integrity of the endothelium.8 HUVEC monolayers
were stained for vinculin, a marker for focal adhesion
formation, and for F-actin. Control cells showed hardly any
vinculin staining and were characterized by cortical F-actin
microfilaments (Figure 3A to 3C), indicating the resting state
of the monolayers. Thrombin induced a dramatic increase in
the formation of focal adhesions and stress fibers (Figure 3G
to 3I). Many small gaps between the cells were observed.
Pretreatment with simvastatin decreased basal F-actin fila-
ments, and only a thin peripheral rim of F-actin remained
(Figure 3D to 3F). Formation of focal adhesions by thrombin
was reduced by simvastatin pretreatment, as was the forma-
tion of stress fibers and of gaps (Figure 3J to 3L). Thus,
simvastatin to a large extent prevented the thrombin-induced
changes of the EC cytoskeleton.
Simvastatin Affects Membrane Translocation
of RhoA
It has been shown previously that the small GTPase RhoA is
involved in the thrombin-induced endothelial hyperperme-
ability and accompanying cytoskeletal rearrangements.9,18,19
Isoprenylation of small GTPases, which is essential for their
translocation to the plasma membrane, is inhibited by
statins.15,20,21
Under resting conditions, a small fraction of the cellular
RhoA content was present in the plasma membrane (Figure
4). Treatment with simvastatin (5 mmol/L for 24 hours)
reduced the membrane localization of RhoA. Stimulation
with thrombin for 30 minutes induced the translocation of
RhoA to the membrane fraction, which was completely
prevented by preincubation with simvastatin. Mevalonate
reversed the effects of simvastatin (data not shown).
Simvastatin Treatment Reduces Vascular Leakage
In Vivo
To test whether simvastatin could improve endothelial barrier
function in vivo, Watanabe rabbits were treated with 15
Figure 3. Thrombin-induced cytoskeletal
reorganization is reduced by simvastatin.
Immunocytochemical staining of vinculin
(A, D, G, and J), F-actin (B, E, H, and K),
or both (C, F, I, and L) is shown.
HUVECs were preincubated for 24 hours
with 5 mmol/L simvastatin (D, E, F, J, K,
and L) and stimulated with 1 U/mL
thrombin for 30 minutes (G, H, I, J, K,
and L) or not treated (A, B, and C). Simi-
lar results were observed in 3 different
cultures.
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mg/kg body wt simvastatin over 4 weeks. Simvastatin in-
duced a slight nonsignificant reduction in plasma cholesterol
(from 10.262.7 mmol/L before to 8.562.1 mmol/L after
simvastatin treatment, P50.30; n53), but cholesterol levels
remained elevated after this relatively short treatment period.
After the animals were euthanized, endothelial barrier func-
tion of the thoracic and abdominal aorta was assessed ex vivo
by determining the penetration of the Evans blue–albumin
complex in the vessel wall. In the thoracic aortas of control
animals, an intense blue staining was observed (Figure 5A).
Treatment with simvastatin reduced Evans blue staining
(Figures 5A and 6). Similar results were obtained in the
abdominal aorta of the same rabbits (Figure 6).
To exclude the possibility that the decrease in endothelial
permeability by simvastatin treatment was due to a reduction
in the extent of atherosclerotic plaques, the same aortic
segments were subsequently stained with oil red O. Aortas
either from control or simvastatin-treated animals were se-
verely atherosclerotic, with no visible changes in lipid accu-
mulation after simvastatin treatment for 4 weeks (Figure 5B).
As a control, umbilical veins, which showed no oil red O
staining, were used (data not shown). It is of interest to note
that in the control animals, a strong blue staining was
observed in the areas of low lipid accumulation (Figure 5A,
white arrow). This extravasation is not likely to be caused by
endothelial damage, because in aortic areas of simvastatin-
treated animals with a comparable low degree of lipid
accumulation (Figure 5B, yellow arrow), a relatively small
amount of Evans blue–albumin complex was observed (Fig-
ure 5A, yellow arrow). This exclusion of Evans blue dye
indicates the presence of an intact endothelial barrier. It is
likely that the accumulated lipids interfered with maximal
accumulation of Evans blue.
Figure 4. Simvastatin (Simva, 5 mmol/L for 24 hours) prevents
thrombin-induced (1 U/mL for 30 minutes) membrane transloca-
tion of RhoA. A, Immunoblots showing effect of Simva on cyto-
solic and membrane-associated RhoA in control and thrombin-
stimulated HUVECs. Equal cytosolic and membrane fractions
were loaded on gel. Because the amount of cytosolic RhoA
under basal conditions was higher compared with membrane-
associated RhoA (see panel B), different exposure times for
cytosolic and membrane fractions are shown. B, Distribution of
RhoA. Blots were quantified by densitometry (mean6SEM of 3
independent experiments).
Figure 5. Simvastatin reduces vascular
leakage in Watanabe rabbits without
regression of presence of atherosclerotic
plaques. A, Groups of 3 Watanabe rab-
bits were treated for 4 weeks with 15
mg/kg body wt simvastatin or placebo
and were euthanized. Aortas were care-
fully prepared, and Evans blue dye
exclusion test was performed as indi-
cated in Methods. B, Afterward, same
aortas were stained with oil red O as
described in Methods. Arrows of same
color indicate corresponding regions in
Evans blue– and oil red O–stained aor-
tas, where less visible atherosclerosis
had developed.
Figure 6. Quantification of Evans blue staining in thoracic and
abdominal parts of rabbit aorta. Groups of 3 Watanabe rabbits
were treated for 4 weeks with 15 mg/kg body wt simvastatin
(hatched bars) or placebo (stippled bars) and were euthanized.
Aortas were carefully prepared, and Evans blue dye exclusion
test was performed. Evans blue intensity was expressed in arbi-
trary units per square millimeter. Values are mean6SEM of 4
determinations in aortas of 3 animals.
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Thus, simvastatin had already improved vascular barrier
function in Watanabe rabbits at a time point at which no
obvious changes in the extent of atherosclerotic plaques were
observed.
Discussion
The major finding of the present study is that simvastatin
treatment reduced endothelial barrier dysfunction both in an
established in vitro model of endothelial permeability con-
sisting of human ECs grown on porous filters and in ex vivo
aortic segments of Watanabe rabbits, which have an increased
endothelial permeability.
Accumulation of LDL in the arterial wall is one of the
hallmarks of the development of atherosclerosis. The focal
nature of plaque formation is remarkably similar to the focal
occurrence of vascular leakage sites.7 In laboratory animals,
the regional variation in the arterial wall permeability predicts
the pattern of experimental atherosclerosis. It is not known at
the moment whether this association reflects a causal rela-
tionship. Our finding, ie, that simvastatin treatment, which
decreases the progression of atherosclerosis, reduces en-
hanced permeability, supports the idea that an increased
permeability to LDL increases the risk of atherosclerosis and
that a reduction in endothelial permeability, in addition to a
lowering in plasma LDL concentration, may assist in the
prevention of the progression of atherosclerosis.
We have previously shown that NO improves the endothe-
lial barrier in vitro and acts as a negative feedback regulator
of the thrombin-induced barrier dysfunction.17 Statins can
increase eNOS expression on the posttranscriptional level in
ECs exposed to oxidizing conditions.15,16 However, during the
relatively short period of our in vitro experiments, the cellular
eNOS antigen concentration did not change. This excluded
the possibility that simvastatin improves barrier function by
increasing NO production. Nor did simvastatin have any
effect on intracellular cAMP concentration, which also im-
proves endothelial barrier function.14
Simvastatin reduced F-actin staining in control HUVEC
monolayers, in accordance with the decrease in F-actin
content by lovastatin treatment in NIH 3T3 cells.22 Further-
more, simvastatin largely reduced the formation of stress
fibers induced by thrombin. This finding is of interest because
prominent stress fibers are found in endothelial cells in vivo
in areas prone to the development of atherosclerosis.6
Several authors have shown that statins may affect the
F-actin cytoskeleton through inactivation of Rho proteins.20,22
Lovastatin prevented the lysophosphatidic acid–induced
translocation of RhoA and cell contraction in neuronal cells
by inhibition of isoprenylation of RhoA.20 An effect of statins
on Rho proteins in vascular smooth muscle and ECs has also
recently been indicated.15,21 We and others have previously
shown that RhoA is involved in the thrombin-induced endo-
thelial barrier dysfunction in vitro, which involves Rho
kinase–dependent inhibition of myosin light chain phosphor-
ylation.9,18,19 In accordance, we now demonstrate that simva-
statin prevents both the basal and the thrombin-induced
translocation of RhoA to the plasma membrane. In these
experiments, compared with other studies,15 a low fraction of
RhoA was present in the plasma membrane under resting
conditions. This explains that no accompanying increase in
cytosolic RhoA was observed after treatment with simvasta-
tin. To our knowledge, no in vivo data are yet available on the
role of activation of RhoA in vascular leakage.
Improvement of endothelial integrity by simvastatin in
vivo was probably not due to a reduction of atherosclerotic
lesions. A short regimen of 4 weeks of simvastatin treatment
was chosen, which had only a moderate effect on plasma
cholesterol levels (17% reduction). No visible plaque regres-
sion was detectable in the rabbit aortas after oil red O
staining. We cannot exclude the possibility that circulating
LDL in the control animals contains an endothelium-
activating fraction, which is reduced in parallel with the drop
in plasma cholesterol. However, we feel more likely that the
prevention of RhoA activation explains the improved barrier
function.
Highly confluent cells were required to demonstrate the
positive effect of simvastatin on disturbed barrier function in
vitro (authors’ unpublished data, 2000). One explanation for
this finding may be that because statins are known to inhibit
cell proliferation, nonconfluent monolayers were not able to
reach confluence in the presence of simvastatin.23 Further-
more, in vascular smooth muscle cells, statins are known to
induce apoptosis at high concentration.21 Taken together,
these findings suggest that care has to be taken to use statins
when endothelial cells are in a proliferative state, eg, in
wound healing.
Treatment of patients suffering from prolonged edema has
been less successful with current therapies until now. Al-
though b-adrenergic agents have been shown to be effective
in acutely induced vascular leakage, when they are adminis-
tered in the presence of capillary leakage syndrome, desen-
sitization to b-adrenergic agents occurs after 1 day.24 Future
studies are necessary to investigate whether statin treatment
could reduce vascular leakage under these conditions. The
recent finding that simvastatin reduces leukocyte-
endothelium interactions indicates that statins also have an
effect on the microvascular endothelium.25 Our finding may
also bear importance for stented vascular areas, inasmuch as
previous work has demonstrated prolonged leakage in these
areas.26
In conclusion, we found that simvastatin, in a relatively
high concentration, reduces endothelial permeability and that
this decrease in permeability was accompanied by a decrease
in cell F-actin content. These findings may have implications
for the treatment of patients with a high risk of developing
atherosclerosis and of those with implanted stents and possi-
bly of patients with capillary leakage syndrome.
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